Breaking Finance News

Ionis Pharmaceuticals Inc (NASDAQ:IONS) stock price target increased to $38.22, issued a report today by Vetr Inc.

Ionis Pharmaceuticals Inc (NASDAQ:IONS) had its target bumped up to $38.22 by Vetr Inc. in an issued report announced 12/01/2016. The bumped up target suggests a potential downside of -0.08% from the company's last stock close price.

Just yesterday Ionis Pharmaceuticals Inc (NASDAQ:IONS) traded -5.55% lower at $41.38. The company’s 50-day moving average is $34.61 and its two hundred day average is $30.81. With the last close up 34.14% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.03% over the date range. Volume of trade was down over the average, with 0 shares of IONS changing hands under the typical 2,289,950

See Chart Below

Ionis Pharmaceuticals Inc (NASDAQ:IONS)

With a total market value of $0, Ionis Pharmaceuticals Inc has with a one year low of $19.59 and a one year high of $63.71 .

A total of 9 equity analysts have released a research note on IONS. 1 firm rating the stock a strong buy, five brokerages rating the company a buy, five brokerages rating the stock a hold, 0 brokers rating the stock a underperform, and finally one analyst rating the company a sell with a 12-month price target of $52.56.

More About Ionis Pharmaceuticals Inc (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company's Ionis Core segment is developing a drug discovery platform. The Company's Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.